Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky

Investigation focuses on RDY losses after Dr. Reddy's disclosed a ₹2.4 billion provision tied to out-of-spec semaglutide batches and shares fell approximately 9%. NEW YORK, July 31, 2026 /PRNewswire/ -- On July 22, 2026, Dr. Reddy's Laboratories (NYSE: RDY) shares fell approximately 9%...